Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy

Urology

Volumn 51, Issue 6, 1998, Pages 978-984

  Levesque, Peter E ^a   Nieh, Peter T ^a   Zinman, Leonard N ^a   Seldin, David W ^a   Libertino, John A ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CYT356; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BEAM THERAPY; CANCER LOCALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; LYMPH NODE DISSECTION; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; RADIATION FIELD;

ADULT; AGED; ANTIBODIES, MONOCLONAL; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0032101091     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00025-9     Document Type: Article

References (17)

1. Zietman A.L., Edelstein R.A., Coen J.J., et al. Radical prostatectomy for adenocarcinoma of the prostate the influence of preoperative and pathologic findings on biochemical disease-free outcome . Urology. 43:1994;828-833.
2. Lerner S.E., Blute M.L., Bengstralh E.J., et al. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol. 156:1996;137-143.
3. Wright G.E. Jr, Haley C., Beckett M.L., et al. Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues. Urol Oncol. 1:1995;18-28.
4. 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol. 152:(5 Pt 1):1994;1490-1495.
5. Foster L.S., Jajodia P., Fournier G. Jr, et al. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol. 149:1993;1024-1028.
6. 111In-Cyt-356 localizes extraprostatic recurrence after prostatectomy (abstract). J Urol. 153:1995;519A.
7. Platt J.F., Bree R.L., Schwab R.E. The accuracy of CT in the staging of carcinoma of the prostate. Am J Roentgenol. 149:1987;315-318.
8. Brendler C.B., Cleeve L.K., Anderson E.E., et al. Staging pelvic lymphadenectomy for carcinoma of the prostate risk versus benefit . J Urol. 124:1980;849-850.
9. Golimbu M., Morales P., Al-Askari S., et al. Extended pelvic lymphadenectomy for prostatic cancer. J Urol. 121:1979;617-620.
10. McDowell G.C. II, Johnson J.W., Tenney D.M., et al. Pelvic lymphadenectomy for staging clinically localized prostate cancer indications, complications, and results in 217 cases . Urology. 35:1990;476-482.
11. Edelstein R.A., Zietman A.L., de las Morenas A., et al. Implications of prostate micrometastases in pelvic lymph nodes an archival tissue study . Urology. 47:1996;370-375.
12. Schild S.E., Buskirk S.J., Wong W.W., et al. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol. 156:1996;1725-1729.
13. Coetzee L.J., Hars V., Paulson D.F. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology. 47:1996;232-235.
14. Partin A.W., Pearson J.D., Landis P.K., et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 43:1994;649-659.
15. D'Amico A.V., Whittington R., Malkowicz S.B., et al. An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins implications on the use of adjuvant therapy . Urology. 47:1996;538-547.
16. Labrie F., Candas B., Cusan L., et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology. 47:1996;212-217.
17. Gilliland F.D., Hunt W.C., Key C.R. Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen era. Urology. 48:1996;67-71.